BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26522004)

  • 1. Usefulness of (18)F-FDG PET/CT in recurrent basal cell carcinoma: Report of a case.
    Ayala S; Perlaza P; Puig S; Prats E; Vidal-Sicart S
    Rev Esp Med Nucl Imagen Mol; 2016; 35(2):124-6. PubMed ID: 26522004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Globe-sparing surgery for medial canthal Basal cell carcinoma with anterior orbital invasion.
    Madge SN; Khine AA; Thaller VT; Davis G; Malhotra R; McNab A; O'Donnell B; Selva D
    Ophthalmology; 2010 Nov; 117(11):2222-8. PubMed ID: 20570356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib.
    Thacker CA; Weiss GJ; Tibes R; Blaydorn L; Downhour M; White E; Baldwin J; Hoff DD; Korn RL
    Cancer Med; 2012 Oct; 1(2):230-6. PubMed ID: 23342272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-Dimensional Image Fusion of
    Yu Y; Zhang WB; Liu XJ; Guo CB; Yu GY; Peng X
    J Oral Maxillofac Surg; 2017 Jun; 75(6):1301.e1-1301.e15. PubMed ID: 28320612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative Contrast-Enhanced CT Versus ¹⁸F-FDG PET/CT Evaluation and the Prognostic Value of Extranodal Extension for Surgical Patients with Head and Neck Squamous Cell Carcinoma.
    Lee JR; Choi YJ; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1020-7. PubMed ID: 26122372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography for basal cell carcinoma of the head and neck.
    Fosko SW; Hu W; Cook TF; Lowe VJ
    Arch Dermatol; 2003 Sep; 139(9):1141-6. PubMed ID: 12975155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of clinical impact of
    Liu J; Larcos G; Howle J; Veness M
    Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. F-18 FDG PET as an imaging tool for detecting and staging metastatic basal-cell carcinoma.
    Niederkohr RD; Gamie SH
    Clin Nucl Med; 2007 Jun; 32(6):491-2. PubMed ID: 17515767
    [No Abstract]   [Full Text] [Related]  

  • 15. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Zhang J; Zhang Y; Jiang Y; Xu A; Wang Y
    BMC Womens Health; 2024 May; 24(1):310. PubMed ID: 38802808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution.
    George A; Girault S; Testard A; Delva R; Soulié P; Couturier OF; Morel O
    Nucl Med Commun; 2014 Mar; 35(3):282-90. PubMed ID: 24240193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 18F-FDG PET and PET/CT in the evaluation of primary cutaneous lymphoma.
    Qiu L; Tu G; Li J; Chen Y
    Nucl Med Commun; 2017 Feb; 38(2):106-116. PubMed ID: 27792043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
    Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
    J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.